Orbital Therapeutics
Aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease.
| USD | 2023 |
|---|---|
| Revenues | 0000 |
| EBITDA | 0000 |
| Profit | 0000 |
| EV | 0000 |
| EV / revenue | 00.0x |
| EV / EBITDA | 00.0x |
| R&D budget | 0000 |
Source: Dealroom estimates
Related Content
Orbital Therapeutics is a pioneering startup in the field of RNA-based medicines, excluding small interfering RNA. The company is leveraging the power of RNA technology, delivery methods, data science, and automation to create a unique platform for the development of a broad range of medicines. Initially, the focus is on vaccines, immunomodulation, and protein replacement.
The company's mission is to improve global health by unlocking the full potential of RNA medicines to treat diseases in ways that were previously unattainable. The market it operates in is the pharmaceutical and biotechnology industry, specifically in the area of genetic medicine and RNA development and delivery.
Orbital Therapeutics' business model is based on the development and commercialization of RNA-based medicines. It generates revenue through the sale of these innovative medicines to healthcare providers and patients. The company's clients are primarily healthcare providers who administer the medicines to patients suffering from various diseases that can be treated with RNA-based therapies.
The company was founded by experts in genetic medicine and RNA development and delivery, including Dr. Giuseppe Ciaramella, who has over 20 years of drug discovery experience at leading pharmaceutical companies. Dr. Ciaramella's extensive experience in the field of antivirals, immunology, and biotherapeutics is instrumental in guiding the company's strategic direction and research efforts.
Keywords: RNA-based medicines, genetic medicine, vaccines, immunomodulation, protein replacement, drug discovery, healthcare providers, pharmaceutical industry, biotechnology industry, RNA technology.